- Home
- CHEB vs SKYE Comparison
CHEB vs SKYE Comparison
Compare CHEB & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEB
- SKYE
- Stock Information
- Founded
- CHEB 2024
- SKYE 2012
- Country
- CHEB Singapore
- SKYE United States
- Employees
- CHEB N/A
- SKYE N/A
- Industry
- CHEB
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CHEB
- SKYE Health Care
- Exchange
- CHEB NYSE
- SKYE Nasdaq
- Market Cap
- CHEB 115.7M
- SKYE 108.3M
- IPO Year
- CHEB 2024
- SKYE N/A
- Fundamental
- Price
- CHEB $10.06
- SKYE $4.95
- Analyst Decision
- CHEB
- SKYE Buy
- Analyst Count
- CHEB 0
- SKYE 6
- Target Price
- CHEB N/A
- SKYE $18.67
- AVG Volume (30 Days)
- CHEB 1.8K
- SKYE 195.9K
- Earning Date
- CHEB 01-01-0001
- SKYE 11-07-2024
- Dividend Yield
- CHEB N/A
- SKYE N/A
- EPS Growth
- CHEB N/A
- SKYE N/A
- EPS
- CHEB N/A
- SKYE N/A
- Revenue
- CHEB N/A
- SKYE N/A
- Revenue This Year
- CHEB N/A
- SKYE N/A
- Revenue Next Year
- CHEB N/A
- SKYE N/A
- P/E Ratio
- CHEB N/A
- SKYE N/A
- Revenue Growth
- CHEB N/A
- SKYE N/A
- 52 Week Low
- CHEB $9.96
- SKYE $1.44
- 52 Week High
- CHEB $26.25
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- CHEB N/A
- SKYE 47.26
- Support Level
- CHEB N/A
- SKYE $5.16
- Resistance Level
- CHEB N/A
- SKYE $5.67
- Average True Range (ATR)
- CHEB 0.00
- SKYE 0.51
- MACD
- CHEB 0.00
- SKYE -0.03
- Stochastic Oscillator
- CHEB 0.00
- SKYE 38.41
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.